Sirolimus coated balloon treatment for below the knee arterial disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness and safety of a sirolimus drug coated balloon (DCB) compared to standard balloon angioplasty for treating below the knee arterial disease. It is a randomized, placebo-controlled, single-blind trial conducted at approximately 70 sites, primarily in the USA, Singapore, Australia, and Japan. Eligible participants will be randomly assigned to receive either the sirolimus DCB in addition to standard angioplasty or a placebo balloon angioplasty. The study aims to determine if the sirolimus DCB can provide better outcomes in terms of reducing restenosis and improving limb health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 21 years or minimum age (is allowed the inclusion of subjects \> 21 years OR adulthood minimum age (depending on the US state regulations)
2. Rutherford class 4 with documented WIFI score, not exceeding more than 30% of target patient population.
3. Rutherford class 5 to 6 in the target limb with documented WIFI score.

   Intraoperative Inclusion Criteria:
4. Single or sequential de novo or re-stenotic lesions (stenosis of \> 50% or occlusions) from 2 to 20cm in the proximal 200mm of below the knee arteries. Lesion is considered as one lesion if there is maximum of 30 mm gap between lesions at discretion of investigator. Below the knee arteries are Tibio-peroneal trunk, Peroneal bifurcation, anterior tibial artery, posterior tibial artery and peroneal artery. With documented Distal Run off a maximum of two tibial vessels can be treated in the index procedure. Inflow free from flow limiting lesions (\<50% stenosis) confirmed by duplex or angiography. Subjects with flow limiting inflow lesions (\>50% stenosis) can be included if lesion had been treated successfully (\<30% residual stenosis) before or during the index procedure.
5. Target vessel has angiographically documented unimpaired (\<50% stenosis) run off into a named Tibio-pedal artery (Peroneal, Anterior Tibial/ Dorsalis Pedis/ Posterior Tibial Artery)

Exclusion Criteria:

1. Comorbid conditions limiting life expectancy ≤ 1 year
2. Subject is currently participating in another investigational drug or device study that has not reached first primary endpoint yet
3. Subject is lactating, pregnant or planning to become pregnant during the course of the study
4. Subject with extensive tissue loss salvageable only with complex foot reconstruction or non-traditional trans metatarsal amputation. This includes subjects with:

   1. Osteomyelitis including and/or proximal to the metatarsal head
   2. Gangrene involving the plantar skin of the forefoot, midfoot,or heel
   3. Deep ulcer or large shallow ulcer (\> 3 cm) involving the plantar skin of the forefoot, midfoot, or heel
   4. Full thickness heel ulcer with/without calcaneal involvement
   5. Any wound with calcaneal bone involvement
   6. Wounds that are deemed to be neuropathic or non-ischemic in nature
   7. Wounds that would require flap coverage or complex wound management for large soft tissue defect
   8. Full thickness wounds on the dorsum of the foot with exposed tendon or bone
5. Prior bypass surgery of target vessel
6. Planned amputation of the target limb (major)
7. Previously implanted stent in the target lesion
8. Vulnerable or protected adults
9. Bleeding diathesis or another disorder (i.e. gastrointestinal ulceration,etc) which would prevent the use of mandated antiplatelet agents
10. Known allergy to sirolimus
11. Subjects with severe (Stage 4) renal disease, defined eGFR \< 30.

    Intraoperative exclusion criteria:
12. Failure to successfully cross the target lesion with a guide wire
13. Target vessel has lesions extending beyond the ankle joint
14. Failure to obtain \<30% residual stenosis prior to randomization
15. Lesions requiring treatment through retrograde access . Retrograde wire crossing is allowed but treatment must be performed from the antegrade approach.
16. Use of commercially available DCBs, bare metal stents, drug eluting stents, specialty balloons or atherectomy devices at the target lesions. (Non-compliant balloons are not considered specialty balloons). For Inflow and non-target lesions all the approved devices are allowed.

Where it's running

• Honor Health Research & Innovation Institute
  Scottsdale, Arizona, United States Recruiting
• Cedars-Sinai Medical Center
  Los Angeles, California, United States Recruiting
• Clearwater Cardiovascular Consultants
  Clearwater, Florida, United States Recruiting
• Baptist Hospital of Miami
  Miami, Florida, United States Recruiting
• University of South Florida
  Tampa, Florida, United States Recruiting
• Vascular Institute of the Midwest
  Davenport, Iowa, United States Recruiting

Study contacts

• Study coordinator: Farhana Siddique
• Email: farhana@conceptmedical.com
• Phone: +919725495366

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prevalence of PAD in Patients With Surgically Treated Lumbar Spinal Stenosis

  This study tests how common peripheral artery disease is in people who have lumbar spinal stenosis and are being considered for, or have had, surgery.

  Recruiting Rennes University Hospital · Lille and 2 other locations · NCT07469020

• Breaking up arterial calcification with intravascular lithotripsy to improve blood flow in people with PAD

  This trial tests whether intravascular lithotripsy plus a drug-coated balloon works better than standard balloon angioplasty plus a drug-coated balloon for people with PAD and heavy artery calcification.

  Recruiting University Hospital, Essen · Essen, North Rhine-Westphalia and 1 other locations · NCT07130526

• Using 3D ultrasound to map vascular problems in people with PAD and related wounds

  This study tests a 3D freehand ultrasound tool to help explain vascular disease to patients and support care at the wound center.

  Recruiting Northwell Health · Lake Success, New York · NCT05134311

• Using bamboo charcoal and probiotics to improve kidney and vascular health in patients with chronic kidney disease and peripheral artery disease

  This study is testing whether bamboo charcoal and probiotics can help improve kidney and blood vessel health in people with chronic kidney disease and peripheral artery disease.

  Recruiting National Taiwan University Hospital · Taipei · NCT04792320

• Sirolimus drug coated balloon treatment for below the knee arterial disease

  This study is testing if a new sirolimus drug-coated balloon can help people with peripheral artery disease have better results than the standard treatment for below the knee arterial problems.

  Recruiting at 17 sites Concept Medical Inc. · Singapore and 19 other locations · NCT04511247

• SGLT2 inhibitors and vascular complications after lower limb revascularization.

  This study will test whether people with peripheral arterial disease who took SGLT2 inhibitors around the time of lower limb revascularization have different rates of major heart or limb problems over the following year compared with those who did not take these drugs.

  Recruiting Wroclaw Medical University · Wroclaw, Lower Silesian Voivodeship · NCT07157475

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.